Drugs / PROSTVAC-F
PROSTVAC-F
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03532217 | Sep 2018 → Apr 2022 | metastatic prostate carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00113984 | Jun 2005 → Feb 2008 | prostate neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/22 trials · 1 met primary | ||||||
| Phase 1/2 | NCT02933255 | Apr 2017 → Jun 2023 | prostate cancer | National Cancer Institute (NCI) | Completed | Met primary |
| Phase 1/2 | NCT00060528 | May 2003 → Mar 2006 | prostate neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 29 trials · 3 missed | ||||||
| Phase 2 | NCT03315871 | Mar 2018 → Jun 2024 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02772562 | Jul 2016 → Apr 2024 | prostate cancer | Medical University of South Carolina | Terminated | No outcome recorded |
| Phase 2 | NCT02649855 | Jan 2016 → Jul 2022 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02649439 | Dec 2015 → Mar 2019 | prostate cancer | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT02153918 | May 2014 → Jul 2017 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01875250 | Jul 2013 → Sep 2019 | prostate cancer | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT00450463 | Feb 2007 → Apr 2017 | prostate cancer | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT00450619 | Feb 2007 → Nov 2012 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00108732 | Feb 2006 → Oct 2010 | grade III prostatic intraepithelial neoplasia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01322490 | Nov 2011 → Sep 2017 | metastatic prostate carcinoma | Bavarian Nordic | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PROSTVAC-F | “PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x10\^9 infectious units.” NCT02933255 ↗8“0.5 ml containing at least 1 x 109 Inf.U PROSTVAC-F given on days 15, 28, 57, 85, 113, 141.” NCT02772562 ↗ “PROSTVAC-F (Fowlpox)/TRICOM” NCT00108732 ↗ |
| Known as | PROSTVAC-F (rilimogene galvacirepvec/rilimogene glafolivec)/TRICOM (triad of costimulatory molecules | “PROSTVAC-F (rilimogene galvacirepvec/rilimogene glafolivec)/TRICOM (triad of costimulatory molecules” NCT00450463 ↗ |
| Known as | PROSTVAC-F/ TRICOM | “PROSTVAC-F/TRICOM (fowlpox) 1 x 10\^9 pfu subcutaneously on days 15, 29, and then every 4 weeks.” NCT00450619 ↗ |
| Known as | Recombinant Fowlpox-PSA (L155)-TRICOM | “Drug: Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)” NCT00060528 ↗ |
| Action | Deplete | “The immune stimulating vaccine will help white blood cells recognize and kill the cancer cells throughout the body.” NCT01875250 ↗ |
| Modality | Vaccine | “a vaccine using recombinant vaccinia virus (prime) and recombinant fowlpox virus (boost)” PMID 17707059 ↗ Aug 2007 |
| Route | Subcutaneous | “Given SC” NCT00108732 ↗ |